Portfolio Value
$1,050,140
+5.01%
Cash
$13
0% of portfolio
Positions
22
$1,050,127 invested
Total P&L
$+50,140
from $1,000,000
Win Rate
N/A
0 total trades
Avg Return
N/A
per trade
⏳
4 stocks queued — will auto-execute at market open (9:45 AM ET / 6:45 AM PT)

⏳ Pending Buys (Tomorrow Open)

TickerCompanyDropAmountRSIVol RatioVolatilityDown DaysVIXY1 ProbY2 Prob
CTSH Cognizant Technology -9.5% $47,992 16 1.2x 48% 1d 17.0 52.4% 0.4
TLK Perusahaan Perseroan -6.8% $47,992 37 0.2x 56% 2d 17.0 52.0% 0.4
TEO Telecom Argentina S. -5.2% $47,992 43 0.9x 77% 4d 17.0 55.2% 0.4
AXTI AXT, Inc. -10.7% $47,992 40 0.8x 163% 2d 16.9 63.1% 0.4

📊 Open Positions

TickerCompanySharesEntryCurrentReturnP&LDaysTypeConf
SMCI Super Micro Computer 1706 $29.30 $30.66 +4.6% $+2,320 10d ML 56%
HIMX Himax Technologies, 2949 $16.95 $18.11 +6.8% $+3,421 10d ML 59%
TNGX Tango Therapeutics, 1735 $28.81 $27.97 -2.9% $-1,457 10d ML 55%
WULF TeraWulf Inc. 2146 $23.29 $28.98 +24.4% $+12,211 10d ML 53%
SKM SK Telecom Co., Ltd. 1357 $36.84 $36.21 -1.7% $-855 10d ML 54%
LCID Lucid Group, Inc. 10683 $4.68 $5.36 +14.5% $+7,264 10d ML 59%
MARA MARA Holdings, Inc. 3965 $12.61 $14.22 +12.8% $+6,384 10d ML 56%
MOS The Mosaic Company 2511 $19.91 $22.90 +15.0% $+7,508 10d ML 52%
RIVN Rivian Automotive, I 3394 $14.73 $16.52 +12.2% $+6,075 10d ML 52%
AD Array Digital Infras 1212 $41.25 $38.86 -5.8% $-2,897 10d ML 53%
PTC PTC Inc. 373 $133.96 $114.75 -14.3% $-7,165 10d ML 51%
ORCL Oracle Corporation 278 $179.67 $184.29 +2.6% $+1,284 10d ML 54%
NAVN Navan, Inc. 2506 $19.95 $21.91 +9.8% $+4,912 10d ML 56%
SATS EchoStar Corporation 433 $115.32 $109.17 -5.3% $-2,663 10d ML 51%
ADBE Adobe Inc. 246 $202.80 $195.16 -3.8% $-1,879 10d ML 51%
RDDT Reddit, Inc. 311 $160.32 $174.96 +9.1% $+4,553 10d ML 55%
PL Planet Labs PBC 1577 $31.70 $28.23 -10.9% $-5,472 10d ML 53%
HIMS Hims & Hers Health, 1833 $27.27 $35.47 +30.1% $+15,031 10d ML 55%
CLOV Clover Health Invest 10224 $4.89 $5.00 +2.2% $+1,125 4d ML 60%
ACN Accenture plc 379 $126.50 $127.98 +1.2% $+561 3d ML 53%
NVCR NovoCure Limited 164 $14.90 $14.28 -4.2% $-102 3d ML 58%
LEGN Legend Biotech Corpo 4 $29.66 $27.93 -5.8% $-7 3d ML 59%

💡 Trade Rationale

Entered 2026-06-19
ACN Accenture plc
ML OPEN Conf: 53% +1.2%
Signal Narrative
ML prob=52.8%
Why We Bought
The drop vastly overweights a 0.5pp guidance reduction in a non-core segment while ignoring robust top-line execution (+6% rev, +9% EPS), disciplined capital allocation ($4.2B buys durable, high-barrier OT security assets), and counter-trend sector strength (XLK +3%). Devil's Advocate concerns are valid but misweight transitory federal softness and near-term M&A dilution against ACN’s proven ability to integrate and monetize strategic acquisitions — Dragos alone serves >70% of Fortune 500 industrial firms, creating immediate cross-sell runway.
What Market Missed (2nd Order)
Strategic repositioning into OT/critical infrastructure security strengthens long-term moat against pure-play AI vendors; acquisitions are accretive beyond FY2027 with cross-sell leverage into ACN’s $12B+ enterprise client base; federal weakness is likely cyclical (Q3 FY2026 federal bookings down 8% QoQ but up 5% YoY), not secular.
Devil's Advocate
["1. U.S. federal spending is highly sensitive to political cycles and budget freezes — a 12% segment showing visible softness may signal broader public-sector demand deterioration, especially amid election-year uncertainty. 2. Guidance cut — even modest — breaks the 'high-single-digit growth' narrative investors priced in for AI-enabled consulting; market may be discounting structural margin compression from AI tooling commoditization. 3. $4.2B acquisition is dilutive near-term (estimated 3–5c EPS drag in FY2027), and Dragos/runZero/NetRise collectively represent <1% of ACN’s current revenue — execution risk outweighs strategic logic at this scale."]
Risk Factors
U.S. federal budget sequestration escalates unexpectedly | Dragos integration delays or client attrition post-acquisition | Broad-based enterprise IT spending freeze triggered by recession
Expected Recovery
14–21 trading days
Entry: $126.50
Current: $127.98
Stop Loss: -99%
Take Profit: +99%
NVCR NovoCure Limited
ML OPEN Conf: 58% -4.2%
Signal Narrative
ML prob=58.1%
Why We Bought
While TRIDENT’s OS miss is real and materially delays growth, the market conflates 'no first-line OS benefit in an aggressive concurrent regimen' with 'TTFields inefficacy' — ignoring EF-14’s validated 4.9-month OS gain in methylated patients, robust PFS signal in TRIDENT, and zero erosion of current $500M+ revenue stream. Unlike true pipeline collapses (e.g., biotech with no approved product), NVCR retains FDA-approved label, pricing power, and positive cash flow — making -20% a classic overreaction to a setback, not a fundamental collapse.
What Market Missed (2nd Order)
Increased valuation discount for clinical-stage medtech due to heightened regulatory risk perception; possible delay or de-prioritization of other TTFields expansions (e.g., mesothelioma, NSCLC); but existing commercial infrastructure, cash flow ($350M+ annual FCF), and durable patient retention (>85% 12-month adherence) remain fully intact.
Devil's Advocate
["TRIDENT was the largest and most pivotal trial for NVCR's near-term growth story — its failure removes the only clear path to meaningful revenue expansion in the next 3–5 years.", 'First-line GBM represents ~65% of the total GBM addressable market; missing OS here severely constrains peak sales potential and raises doubts about biological activity in treatment-naïve microenvironments.', 'Investors reasonably fear regulatory scrutiny on existing label (EF-14 was also first-line but in *methylated MGMT* patients only) and potential payer pushback if real-world evidence fails to replicate prior OS benefit.']
Risk Factors
FDA may request additional analyses or impose labeling restrictions on current use | Key opinion leader sentiment shifts negatively post-data, impacting physician adoption | Near-term liquidity pressure if follow-on financing is misinterpreted as distress
Expected Recovery
21–45 days
Entry: $14.90
Current: $14.28
Stop Loss: -99%
Take Profit: +99%
LEGN Legend Biotech Corporatio
ML OPEN Conf: 59% -5.8%
Signal Narrative
ML prob=58.6%
Entry: $29.66
Current: $27.93
Stop Loss: -99%
Take Profit: +99%
Entered 2026-06-18
CLOV Clover Health Investments
ML OPEN Conf: 60% +2.2%
Signal Narrative
ML prob=60.4%
Entry: $4.89
Current: $5.00
Stop Loss: -99%
Take Profit: +99%
Entered 2026-06-12
SMCI Super Micro Computer, Inc
ML OPEN Conf: 56% +4.6%
Signal Narrative
ML prob=56.2%
Entry: $29.30
Current: $30.66
Stop Loss: -99%
Take Profit: +99%
HIMX Himax Technologies, Inc.
ML OPEN Conf: 59% +6.8%
Signal Narrative
ML prob=58.7%
Why We Bought
HIMX的超额跌幅达-8.9%，但触发因素是SemiAnalysis的CPO技术延迟报告——这是分析师观点而非公司公告或确定性事件。HIMX的核心收入来自显示驱动IC而非CPO，CPO业务占比有限，板块性恐慌导致的抛售可能过度惩罚了HIMX。Devil's advocate中关于'成长溢价压缩'的论点有一定道理，但-11%的跌幅对于一个边缘业务的技术延迟报告而言仍显过度。不过，由于信息源是分析师报告而非公司公告，且HIMX的CPO业务实际占比和估值贡献难以精确量化，置信度受限。
What Market Missed (2nd Order)
如果CPO延迟是暂时性的（技术路线未变，只是时间表推迟），市场可能在恐慌消退后重新定价；但如果延迟意味着技术路线存在根本性障碍，则HIMX的硅光子/WLO业务前景需要重新评估
Devil's Advocate
1) HIMX近年来积极布局CPO/硅光子领域，市场给予的估值溢价中包含了CPO成长预期，如果CPO技术延迟是真实的，这部分溢价理应被压缩，-11%可能反映的是成长故事的折价而非仅仅是当前业务的影响；2) HIMX市值仅$2.8B，属于中小盘半导体股，流动性相对有限，在板块性恐慌中容易出现超额波动，且机构持仓调整可能放大跌幅；3) 显示驱动IC本身是周期性业务，当前全球消费电子需求复苏力度存疑，如果CPO这个增长引擎也出现延迟，HIMX可能面临'旧业务周期性+新业务延迟'的双重压力，分析师看空文章可能反映了更深层的基本面担忧
Risk Factors
CPO技术延迟可能比预期更严重，影响HIMX长期成长叙事 | 显示驱动IC核心业务可能面临周期性下行压力 | 中小盘半导体股在宏观不确定性中可能持续承压
Expected Recovery
2-4周
Entry: $16.95
Current: $18.11
Stop Loss: -99%
Take Profit: +99%
TNGX Tango Therapeutics, Inc.
ML OPEN Conf: 55% -2.9%
Signal Narrative
ML prob=55.1%
Entry: $28.81
Current: $27.97
Stop Loss: -99%
Take Profit: +99%
WULF TeraWulf Inc.
ML OPEN Conf: 53% +24.4%
Signal Narrative
ML prob=53.4%
Entry: $23.29
Current: $28.98
Stop Loss: -99%
Take Profit: +99%
SKM SK Telecom Co., Ltd.
ML OPEN Conf: 54% -1.7%
Signal Narrative
ML prob=53.6%
Entry: $36.84
Current: $36.21
Stop Loss: -99%
Take Profit: +99%
LCID Lucid Group, Inc.
ML OPEN Conf: 59% +14.5%
Signal Narrative
ML prob=59.3%
Entry: $4.68
Current: $5.36
Stop Loss: -99%
Take Profit: +99%
MARA MARA Holdings, Inc.
ML OPEN Conf: 56% +12.8%
Signal Narrative
ML prob=55.9%
Entry: $12.61
Current: $14.22
Stop Loss: -99%
Take Profit: +99%
MOS The Mosaic Company
ML OPEN Conf: 52% +15.0%
Signal Narrative
ML prob=51.5%
Entry: $19.91
Current: $22.90
Stop Loss: -99%
Take Profit: +99%
RIVN Rivian Automotive, Inc.
ML OPEN Conf: 52% +12.2%
Signal Narrative
ML prob=51.9%
Entry: $14.73
Current: $16.52
Stop Loss: -99%
Take Profit: +99%
AD Array Digital Infrastruct
ML OPEN Conf: 53% -5.8%
Signal Narrative
ML prob=52.8%
Entry: $41.25
Current: $38.86
Stop Loss: -99%
Take Profit: +99%
PTC PTC Inc.
ML OPEN Conf: 51% -14.3%
Signal Narrative
ML prob=50.7%
Why We Bought
PTC的-12.36%跌幅完全由Oracle sympathy selling驱动，自身无任何负面基本面消息，反而在密集发布AI产品创新。Devil's advocate中最有力的论点是AI基础设施投资可能挤压应用软件预算，但这是中期假设而非已证实的趋势，且PTC的客户群（制造业）的PLM/CAD支出相对刚性，不太可能因AI infra投资而大幅削减。跌幅超过Oracle本身（-11%）且在大盘+1.7%、板块+3.7%的背景下，过度反应的概率较高。但confidence受限于：信息源主要是市场情绪而非确定性事件，且PTC估值本身不算便宜，回弹幅度可能有限。
What Market Missed (2nd Order)
如果Oracle的融资担忧被证明是过度反应（Oracle后续股价企稳），PTC等被误伤的软件股可能快速反弹。PTC的AI产品发布如果在后续季度体现在ARR增长中，将成为催化剂。但如果企业AI基础设施投资确实挤压应用软件预算，整个工业软件板块可能面临持续估值压缩
Devil's Advocate
1) PTC市值仅$13.7B，相对小盘软件股在恐慌中流动性差，跌幅放大是结构性的，不代表会快速回弹；2) Oracle的$40B融资计划暗示AI基础设施投资可能挤压企业在应用软件（如PTC的PLM/CAD）上的预算分配，这对PTC的中期需求是真实威胁——如果客户把IT预算转向AI基础设施，PTC的订阅增长可能放缓；3) PTC当前估值即使跌后仍不便宜（$13.7B市值对应其ARR约$2B，P/S约7x），在利率环境和AI投资不确定性下，市场可能在重新定价整个工业软件板块的合理估值；4) PTC密集发布AI产品可能被市场解读为'AI washing'——产品发布多但变现能力未经验证，投资者可能持怀疑态度
Risk Factors
Oracle融资担忧扩散为更广泛的软件板块估值重估 | PTC下一季度财报如果ARR增长放缓将验证bearish thesis | AI产品发布未能转化为实际收入增长导致估值进一步压缩
Expected Recovery
1-3周回收60-80%跌幅
Entry: $133.96
Current: $114.75
Stop Loss: -99%
Take Profit: +99%
ORCL Oracle Corporation
ML OPEN Conf: 54% +2.6%
Signal Narrative
ML prob=53.9%
Why We Bought
Record Q4 beat + 大跌是经典的beat-and-dump过度反应信号。虽然$40B融资（含股权稀释）是合理担忧，但8.5%跌幅（超额-12.3%）对于一家AI需求强劲、刚签下大型政府合同的公司来说过度了。Devil's advocate关于稀释和CapEx回报不确定性的论点有效，但历史上AI周期中类似的CapEx恐慌（Microsoft、Amazon）多在2-4周内恢复。Oracle的风险溢价应增加，但不至于一天抹去$17/股。
What Market Missed (2nd Order)
如果AI云RPO持续强劲增长，FY2028-2029收入加速将证明CapEx合理性；联邦政府合同增强长期收入可见性；Oracle多云合作策略降低了AI投资的集中风险
Devil's Advocate
1) $40B融资含股权部分将实质性稀释股东，在已高估值基础上是真实负面；2) Oracle作为云市场第二梯队，AI CapEx军备竞赛的回报不确定性高于AWS/Azure；3) 股价年内已大幅上涨，估值已price in大量增长预期，CapEx超预期打破了'高增长+高利润率'的叙事
Risk Factors
股权融资比例超预期导致进一步稀释担忧 | AI CapEx回报周期长于预期，FY2028收入不及预期 | 云市场竞争加剧，Oracle市场份额增长放缓
Expected Recovery
2-4周（需下一季度AI云收入数据验证）
Entry: $179.67
Current: $184.29
Stop Loss: -99%
Take Profit: +99%
NAVN Navan, Inc.
ML OPEN Conf: 56% +9.8%
Signal Narrative
ML prob=55.9%
Why We Bought
6家分析师全部维持Buy并上调目标价（最低$26 vs 当前$20.14）是极强的正面信号，与-11%跌幅形成鲜明矛盾。Devil's advocate中'sell the news'论点有一定道理，但无法解释为何0/6分析师转为负面；成交量萎缩68%确认这是流动性驱动的获利了结而非基本面恶化。分析师目标价基于公告后的最新信息，confidence可达72%。
What Market Missed (2nd Order)
6家分析师上调目标价将在未来1-2周吸引新机构买盘；低成交量下跌意味着卖压有限，反弹阻力小
Devil's Advocate
1) 股价财报前已从$15-18涨至$22.63，好消息可能已price in，$20是合理均衡价；2) Forward guidance可能仅in-line，增长放缓预期导致SaaS估值压缩；3) 公司可能仍在亏损，$5.1B市值存在估值压力
Risk Factors
财报具体guidance细节未知，可能存在隐藏的增长放缓信号 | SaaS板块整体估值如果承压会拖累反弹 | 公司可能仍处于亏损阶段，盈利时间表不确定性高
Expected Recovery
7-14天
Entry: $19.95
Current: $21.91
Stop Loss: -99%
Take Profit: +99%
SATS EchoStar Corporation
ML OPEN Conf: 51% -5.3%
Signal Narrative
ML prob=50.8%
Why We Bought
基于未确认传言的-8.33%跌幅明显过度。即使SpaceX-xAI合并成真，对EchoStar的实际业务影响有限，因为SpaceX已是现有竞争对手。市场可能忽略了EchoStar在企业服务和地面网络的差异化优势。
What Market Missed (2nd Order)
可能影响整个卫星通信板块估值，但也可能凸显行业整合价值
Devil's Advocate
1) SpaceX-xAI合并可能创造更强大的卫星通信+AI综合平台，威胁EchoStar市场份额；2) 股价已从低位大幅上涨，估值可能偏高，任何负面消息都容易引发获利了结；3) 卫星通信行业竞争日趋激烈，利润率面临长期压力
Risk Factors
传言成真且影响超预期 | 整体科技股调整 | 卫星通信行业估值重估
Expected Recovery
1-2周内回到$130-135区间
Entry: $115.32
Current: $109.17
Stop Loss: -99%
Take Profit: +99%
ADBE Adobe Inc.
ML OPEN Conf: 51% -3.8%
Signal Narrative
ML prob=51.1%
Why We Bought
Adobe交出了beat-and-raise的财报，基本面没有恶化，两日15%的跌幅主要由CFO离职+分析师降级+AI恐慌叙事驱动。对于Devil's Advocate的回应：1) CFO是被Marvell高薪挖走而非主动逃离，离职时机与财报重合更像是Marvell的策略而非Adobe的问题；2) AI威胁是真实的长期风险，但本季度AI产品需求强劲恰恰说明Adobe正在受益于AI而非被颠覆；3) 分析师降级的理由（增长不确定性）与实际beat-and-raise的数据矛盾，更像是事后找理由。但confidence不设太高，因为多重负面催化剂叠加可能需要时间消化，且AI竞争威胁确实是真实的结构性风险。
What Market Missed (2nd Order)
1) CFO空缺期间可能影响资本配置决策（回购、并购节奏）；2) 但Adobe作为成熟软件公司，CFO更换对产品和技术路线影响有限；3) 大幅下跌后可能触发价值型基金的买入兴趣
Devil's Advocate
1) CFO离职时机敏感——在财报发布同期离开，可能暗示其对Adobe未来财务前景信心不足，或者内部存在战略分歧；2) AI对Adobe的威胁是结构性的——Canva、Figma替代品+开源AI生成工具正在侵蚀Adobe的护城河，no-paywall策略可能是被迫之举而非主动选择，暗示定价权下降；3) 多家分析师同时降级不是巧合——RBC等机构可能掌握更多渠道调研信息，beat-and-raise的质量可能不高（如一次性因素、低质量收入增长），市场对$82B市值的Adobe给予更高的增长门槛是合理的
Risk Factors
AI竞争工具持续侵蚀Adobe市场份额 | CFO空缺期延长导致更多管理层不确定性 | 分析师进一步降级形成负面共识
Expected Recovery
7-14天
Entry: $202.80
Current: $195.16
Stop Loss: -99%
Take Profit: +99%
RDDT Reddit, Inc.
ML OPEN Conf: 55% +9.1%
Signal Narrative
ML prob=54.7%
Why We Bought
S&P 500排除是纯技术性事件，不改变Reddit强劲的基本面（69%增长、40% EBITDA margin、Q1 beat）。虽然被动卖压真实存在且可能尚未完全消化，但+8%的温和成交量增幅表明恐慌程度有限。历史指数效应研究支持基本面未恶化的被排除股票在2-4周内恢复。$550M AI交易前景提供额外上行催化剂。估值虽不便宜，但这不是新信息，排除前市场已接受这一估值水平。
What Market Missed (2nd Order)
一旦被动卖压消化（通常1-2周），股价回归基本面定价；$550M AI交易若落地将成为强力催化剂，可能推动下次指数调整时重新纳入
Devil's Advocate
1) 被动基金强制卖出是真实机械性卖压，可能持续数日尚未完全释放；2) S&P委员会排除可能暗示对盈利持续性的质疑，Reddit商业模式仍在早期验证阶段；3) $31.6B市值对应的估值倍数不便宜，排除事件可能触发主动基金也重新审视持仓
Risk Factors
被动基金卖压可能持续数日尚未完全释放 | AI授权交易($550M)若未能落地将削弱增长叙事 | 整体科技/成长股估值若遭遇宏观逆风可能放大下行
Expected Recovery
7-14个交易日
Entry: $160.32
Current: $174.96
Stop Loss: -99%
Take Profit: +99%
PL Planet Labs PBC
ML OPEN Conf: 53% -10.9%
Signal Narrative
ML prob=53.1%
Entry: $31.70
Current: $28.23
Stop Loss: -99%
Take Profit: +99%
HIMS Hims & Hers Health, Inc.
ML OPEN Conf: 55% +30.1%
Signal Narrative
ML prob=54.8%
Entry: $27.27
Current: $35.47
Stop Loss: -99%
Take Profit: +99%

📄 Latest Analysis Report

# Signal Performance Report — 2026-06-19 ## Verdict Accuracy ### MISJUDGMENT (7 signals) - ✅ **HIMX** (2026-06-10) drop:-11.2% → Day9:+11.6% [-] conf:55% SemiAnalysis报告指出CPO（共封装光学）关键技术延迟，引发光电子板块 - ✅ **DNTH** (2026-06-10) drop:-9.6% → Day9:+7.9% [-] conf:72% Sanofi终止其CIDP疗法的晚期临床试验（因疗效问题），市场担忧这对Dian - ❌ **PTC** (2026-06-11) drop:-12.4% → Day8:-3.1% [-] conf:62% PTC因Oracle财报后宣布$40B融资计划引发软件板块恐慌性抛售，被视为AI - ✅ **ORCL** (2026-06-11) drop:-8.5% → Day8:+0.1% [-] conf:62% Oracle交出创纪录Q4财报，但宣布FY2027将筹集$40B（债务+股权）用 - ✅ **NAVN** (2026-06-12) drop:-11.0% → Day7:+8.7% [-] conf:62% Navan发布财报后，尽管多家分析师上调目标价并维持买入评级，股价仍大跌11%— - ❌ **ADBE** (2026-06-12) drop:-7.0% → Day7:-4.0% [-] conf:62% Adobe CFO Dan Durn离职跳槽至Marvell，叠加分析师下调评级 - ✅ **RDDT** (2026-06-12) drop:-7.3% → Day7:+8.9% [-] conf:62% Reddit被排除出S&P 500指数，触发被动资金抛售和市场对其地位的重新评估 **Accuracy: 5/7 (71%)** ### CORRECT (7 signals) - ✅ **SMCI** (2026-06-10) drop:-18.1% → Day9:-7.9% [-] conf:75% SMCI宣布70亿美元股权融资计划，市场担忧大规模稀释现有股东权益，尽管公司同时 - ❌ **LCID** (2026-06-10) drop:-8.7% → Day9:+14.0% [-] conf:75% Lucid股价跌至历史新低，SeekingAlpha下调评级，叠加证券集体诉讼、 - ❌ **MARA** (2026-06-10) drop:-5.2% → Day9:+12.7% [-] conf:68% 比特币价格下跌叠加大盘回调，拖累MARA等比特币矿业/持仓公司股价；同时分析师因 - ❌ **MOS** (2026-06-10) drop:-6.9% → Day9:+15.5% [-] conf:62% MOS在财报发布30天后持续下跌，叠加大盘和板块整体走弱，股价创52周新低，市场 - ❌ **RIVN** (2026-06-10) drop:-6.2% → Day9:+11.9% [-] conf:62% Rivian开始交付R2车型，但市场对其'平价'定位产生质疑，消费者认为相比Te - ❌ **NAMSW** (2026-06-09) drop:-5.0% → Day10:+0.5% [-] conf:70% 大盘下跌1.6%拖累小盘生物制药股，叠加成交量放大可能有部分获利了结 - ❌ **CLOV** (2026-06-12) drop:-5.3% → Day7:+7.8% [-] conf:65% CLOV在法院判决推动星级评级升级后暴涨18.9%，次日回落5.3%属于典型的利 **Accuracy: 1/7 (14%)** ### UNCLEAR (11 signals) - ❓ **SKM** (2026-06-10) drop:-6.6% → Day9:-5.9% [-] conf:45% SKM随AI/科技硬件板块抛售下跌，市场将其归类为AI概念股（量子安全+AI校准 - ❓ **WULF** (2026-06-10) drop:-5.7% → Day9:+21.4% [-] conf:45% TeraWulf宣布增发股票（stock offering），发行价较前收盘价折 - ❓ **QCOM** (2026-06-10) drop:-6.5% → Day9:+17.7% [-] conf:45% 半导体板块整体遭抛售，芯片股集体下跌，QCOM作为高beta半导体股跟随板块下行 - ❓ **INSM** (2026-06-10) drop:-5.1% → Day9:+1.9% [-] conf:45% Insmed在Goldman Sachs医疗会议上的演讲未能提供超预期催化剂，叠 - ❓ **CMCM** (2026-06-10) drop:-9.3% → Day9:-7.7% [-] conf:40% 猎豹移动Q1仍然亏损（EPS -$0.07），尽管同比改善，市场对持续亏损的微型 - ❓ **TNGX** (2026-06-10) drop:-9.1% → Day9:-2.5% [-] conf:45% TNGX在胰腺癌临床数据公布后暴涨50%+后，公司宣布$6亿增发融资+内部人士计 - ❓ **AD** (2026-06-11) drop:-23.4% → Day8:-3.1% [-] conf:30% AD在大盘上涨日暴跌23%触及52周新低，但缺乏明确的催化剂新闻覆盖，可能存在未 - ❓ **SATS** (2026-06-12) drop:-9.0% → Day7:-6.3% [-] conf:45% SpaceX IPO正式上市后，SATS作为SpaceX代理投资标的的稀缺性溢价 - ❓ **PL** (2026-06-12) drop:-6.4% → Day7:-11.7% [-] conf:45% SpaceX即将在Nasdaq上市，投资者从PL等现有太空股中轮动资金转向Spa - ❓ **HIMS** (2026-06-12) drop:-5.5% → Day7:+30.1% [-] conf:45% 多重竞争压力叠加（Eli Lilly GLP-1扩张、WeightWatcher - ❓ **HAWK** (2026-06-12) drop:-5.2% → Day7:-5.8% [-] conf:40% 无明确催化剂的个股下跌，成交量大幅萎缩55%，可能是流动性驱动的价格波动或机构调 ## Missed Opportunities These were NOT flagged as MISJUDGMENT but recovered significantly: - **WULF** judged UNCLEAR → Day9:+21.4% (TeraWulf宣布增发股票（stock offering），发行价较前收盘价折) - **QCOM** judged UNCLEAR → Day9:+17.7% (半导体板块整体遭抛售，芯片股集体下跌，QCOM作为高beta半导体股跟随板块下行) - **LCID** judged CORRECT → Day9:+14.0% (Lucid股价跌至历史新低，SeekingAlpha下调评级，叠加证券集体诉讼、) - **MARA** judged CORRECT → Day9:+12.7% (比特币价格下跌叠加大盘回调，拖累MARA等比特币矿业/持仓公司股价；同时分析师因) - **MOS** judged CORRECT → Day9:+15.5% (MOS在财报发布30天后持续下跌，叠加大盘和板块整体走弱，股价创52周新低，市场) - **RIVN** judged CORRECT → Day9:+11.9% (Rivian开始交付R2车型，但市场对其'平价'定位产生质疑，消费者认为相比Te) - **HIMS** judged UNCLEAR → Day7:+30.1% (多重竞争压力叠加（Eli Lilly GLP-1扩张、WeightWatcher) - **CLOV** judged CORRECT → Day7:+7.8% (CLOV在法院判决推动星级评级升级后暴涨18.9%，次日回落5.3%属于典型的利)